WCN26-4322 INTERMITTENT FEBUXOSTAT DOSING PROVIDES SUPERIOR RENOPROTECTION TO CONTINUOUS THERAPY IN PATIENTS WITH CKD (STAGES III-IV) AND HYPERURICEMIA